CY1107678T1 - Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα - Google Patents

Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα

Info

Publication number
CY1107678T1
CY1107678T1 CY20071100805T CY071100805T CY1107678T1 CY 1107678 T1 CY1107678 T1 CY 1107678T1 CY 20071100805 T CY20071100805 T CY 20071100805T CY 071100805 T CY071100805 T CY 071100805T CY 1107678 T1 CY1107678 T1 CY 1107678T1
Authority
CY
Cyprus
Prior art keywords
dna sequences
regulatory sequences
suppressive activity
provides
clarifying
Prior art date
Application number
CY20071100805T
Other languages
English (en)
Inventor
Arie Pieter Otte
Arthur Leo Kruckeberg
Original Assignee
Chromagenics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP01202581A external-priority patent/EP1273666A1/en
Application filed by Chromagenics B.V. filed Critical Chromagenics B.V.
Publication of CY1107678T1 publication Critical patent/CY1107678T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
    • C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

Η εφεύρεση αναφέρεται στην συστηματική αποσαφήνιση και ταυτοποίηση ρυθμιστικών αλληλουχιών. Η εφεύρεση παρέχει μεταξύ των άλλων σαρώσεις και μεθόδους ανίχνευσης με τις οποίες μπορούν να αναγνωρισθούν ρυθμιστικές αλληλουχίες. Η εφεύρεση περαιτέρω παρέχει ρυθμιστικές αλληλουχίες και χρήση αυτών σε διάφορα πεδία όπως είναι, αλλά χωρίς να περιορίζονται σε αυτά, παραγωγή πρωτεΐνης, διαγνωστικά, διαγονιδιακά φυτά και ζώα και θεραπευτικό πεδίο.
CY20071100805T 2001-07-04 2007-06-19 Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα CY1107678T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP01202581A EP1273666A1 (en) 2001-07-04 2001-07-04 Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
US30319901P 2001-07-05 2001-07-05
EP05076209A EP1600510B1 (en) 2001-07-04 2002-06-14 DNA sequences having anti-repressor activity
US10/190,312 US7192741B2 (en) 2001-07-04 2002-07-05 DNA sequences comprising gene transcription regulatory qualities and methods for detecting and using such DNA sequences

Publications (1)

Publication Number Publication Date
CY1107678T1 true CY1107678T1 (el) 2013-04-18

Family

ID=47915807

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100805T CY1107678T1 (el) 2001-07-04 2007-06-19 Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα

Country Status (22)

Country Link
US (9) US7192741B2 (el)
EP (8) EP1600510B1 (el)
JP (3) JP4500044B2 (el)
KR (2) KR100942117B1 (el)
CN (1) CN1266282C (el)
AT (8) ATE466943T1 (el)
AU (3) AU2002314629B2 (el)
BR (1) BRPI0210771B8 (el)
CA (2) CA2450020C (el)
CY (1) CY1107678T1 (el)
DE (8) DE60236331D1 (el)
DK (8) DK1829971T3 (el)
ES (8) ES2285630T3 (el)
HK (1) HK1068652A1 (el)
IL (4) IL159674A0 (el)
MX (1) MXPA03011801A (el)
NO (1) NO338477B1 (el)
NZ (1) NZ530218A (el)
PT (1) PT1600510E (el)
SG (1) SG143066A1 (el)
WO (1) WO2003004704A2 (el)
ZA (1) ZA200309599B (el)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60236331D1 (de) 2001-07-04 2010-06-17 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
CA2723500C (en) 2002-06-14 2014-10-28 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en) * 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
ES2368733T3 (es) 2002-07-18 2011-11-21 Merus B.V. Producción recombinante de mezclas de anticuerpos.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
NZ540471A (en) 2002-12-18 2008-07-31 Chromagenics Bv A method for improving protein production
AU2003290453A1 (en) 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
DK1670925T3 (da) 2003-10-02 2013-07-08 Crucell Holland Bv Pakningsceller til rekombinat adenovirus
WO2005059149A2 (en) * 2003-12-12 2005-06-30 Chromagenics B.V. Improved protein production
EP1737971B1 (en) 2004-01-20 2017-08-16 Merus N.V. Mixtures of binding proteins
PT1763586E (pt) * 2004-07-08 2008-02-25 Chromagenics Bv Nova sequência para melhorar a expressão de ácido nucleico
EP1786908B1 (en) * 2004-08-18 2010-03-03 Bayer CropScience AG Plants with increased plastidic activity of r3 starch-phosphorylating enzyme
SI1809750T1 (sl) * 2004-11-08 2012-08-31 Chromagenics Bv Izbira gostiteljskih celic, ki imajo visok nivo izraĹľanja proteina
US20100136616A1 (en) * 2004-11-08 2010-06-03 Chromagenics B.V. Selection of Host Cells Expressing Protein at High Levels
CA2581422C (en) 2004-11-08 2012-05-22 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US20060195935A1 (en) * 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
CA2587712C (en) * 2004-11-18 2013-02-12 National University Of Corporation Hiroshima University Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant
US7968700B2 (en) 2006-03-20 2011-06-28 Chromagenics B.V. Expression augmenting DNA fragments, use thereof, and methods for finding thereof
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
US20090142805A1 (en) * 2007-01-08 2009-06-04 Millipore Corporation High expression cell line that eliminates gene amplification
DK2443239T3 (en) 2009-06-15 2016-02-15 Cellagenics B V New stringent selection markers
US8566596B2 (en) 2010-08-24 2013-10-22 Cisco Technology, Inc. Pre-association mechanism to provide detailed description of wireless services
DK2611915T3 (da) 2010-09-01 2015-06-22 Cellagenics B V Nukleinsyrefragmenter fra en ribosomal proteinpromoter til forstærkning af genekspression
MX360109B (es) 2012-04-20 2018-10-23 Merus Nv Metodos y medios para la produccion de moleculas de tipo ig.
US11180572B2 (en) 2012-07-06 2021-11-23 Genmab B.V. Dimeric protein with triple mutations
SI2900694T1 (sl) 2012-09-27 2018-12-31 Merus N.V. Bispecifična IGG protitelesa kot vključitelji T-celic
US10417380B1 (en) 2013-12-31 2019-09-17 Mckesson Corporation Systems and methods for determining and communicating a prescription benefit coverage denial to a prescriber
US10489552B2 (en) 2014-02-14 2019-11-26 Mckesson Corporation Systems and methods for determining and communicating patient incentive information to a prescriber
NZ724013A (en) 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
US10157262B1 (en) 2015-03-10 2018-12-18 Mckesson Corporation Systems and methods for determining patient financial responsibility for multiple prescription products
CN108026174B (zh) 2015-07-10 2023-02-17 美勒斯公司 人cd3结合抗体
AU2016340764B2 (en) 2015-10-23 2023-06-01 Fundació lnstitut de Recerca Biomèdica (IRB Barcelona) Binding molecules that inhibit cancer growth
US11514137B1 (en) 2016-03-30 2022-11-29 Mckesson Corporation Alternative therapy identification system
US10999224B1 (en) 2017-02-01 2021-05-04 Mckesson Corporation Method and apparatus for parsing an electronic message and constructing multiple differently prioritized messages therefrom
EP3600413A1 (en) 2017-03-31 2020-02-05 Merus N.V. Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
MX2020001432A (es) 2017-08-09 2020-03-20 Merus Nv Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).
US10862832B1 (en) 2018-07-24 2020-12-08 Mckesson Corporation Computing system and method for automatically reversing an action indicated by an electronic message
US11043437B2 (en) 2019-01-07 2021-06-22 Applied Materials, Inc. Transparent substrate with light blocking edge exclusion zone
US11562437B1 (en) 2019-06-26 2023-01-24 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
US11636548B1 (en) 2019-06-26 2023-04-25 Mckesson Corporation Method, apparatus, and computer program product for providing estimated prescription costs
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
WO2021155369A1 (en) * 2020-01-31 2021-08-05 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods to identify genetic silencers and applications thereof
US11610240B1 (en) 2020-02-17 2023-03-21 Mckesson Corporation Method, apparatus, and computer program product for partitioning prescription transaction costs in an electronic prescription transaction
IL298394A (en) 2020-05-21 2023-01-01 Merus Nv Methods and means for producing ig-like molecules
US11587657B2 (en) 2020-09-04 2023-02-21 Mckesson Corporation Method, apparatus, and computer program product for performing an alternative evaluation procedure in response to an electronic message

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US719271A (en) * 1902-01-13 1903-01-27 Solomon P Smith Furnace.
US5610053A (en) 1993-04-07 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services DNA sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells
US5972605A (en) * 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
EP0818536A4 (en) * 1995-03-24 2000-09-06 Shionogi & Co DNA MOLECULE DRAWN ON THE SUPPRESSION OF THE GENE EXPRESSION AND CORRESPONDING PROTEIN
DE19539493A1 (de) * 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5773695A (en) 1996-01-26 1998-06-30 North Carolina State University Plant nuclear scaffold attachment region and method for increasing gene expression in transgenic cells
US6037525A (en) * 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO2000005393A2 (en) 1998-07-21 2000-02-03 Cobra Therapeutics Limited A polynucleotide comprising a ubiquitous chromatin opening element (ucoe)
ATE370247T1 (de) * 1998-08-14 2007-09-15 Chromagenics Bv Dns sequenz, verfahren für dessen nachweis und herstellung und ihre benutzung
US6521419B1 (en) 1998-09-22 2003-02-18 Kanakaraju Koduri Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
US6800457B2 (en) 1998-09-22 2004-10-05 Bristol-Myers Squibb Company Expression vectors containing hot spot for increased recombinant protein expression in transfected cells
AU1128400A (en) 1998-10-22 2000-05-08 Medical College Of Georgia Institute, Inc. Long terminal repeat, enhancer, and insulator sequences for use in recombinant vectors
AU784506B2 (en) * 1999-08-25 2006-04-13 Immunex Corporation Compositions and methods for improved cell culture
US20030166042A1 (en) 2000-02-11 2003-09-04 Millennium Pharmaceuticals, Inc. Novel seven-transmembrane proteins/G-protein coupled receptors
US6586205B1 (en) 2000-02-11 2003-07-01 Millennium Pharmaceuticals, Inc. 43239 a novel GPCR-like molecule and uses thereof
EP1430124B1 (en) 2000-09-20 2013-11-06 EMD Millipore Corporation Artificial ubiquitous chromatin opening elements (ucoe)
DE60236331D1 (de) 2001-07-04 2010-06-17 Chromagenics Bv DNS-Sequenzen mit Anti-Repressor-Aktivität
EP1273666A1 (en) 2001-07-04 2003-01-08 Chromagenics B.V. Method of selecting a DNA sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity
CA2723500C (en) * 2002-06-14 2014-10-28 Chromagenics B.V. A method for simultaneous production of multiple proteins; vectors and cells for use therein
WO2003106674A2 (en) 2002-06-14 2003-12-24 Chromagenics B.V. Means and methods for regulating gene expression
NZ540471A (en) 2002-12-18 2008-07-31 Chromagenics Bv A method for improving protein production
AU2003290453A1 (en) 2002-12-20 2004-07-14 Chromagenics B.V. Means and methods for producing a protein through chromatin openers that are capable of rendering chromatin more accessible to transcription factors

Also Published As

Publication number Publication date
US20070037256A1 (en) 2007-02-15
AU2002314629B2 (en) 2007-08-30
AU2007234619A1 (en) 2007-12-13
EP1600510B1 (en) 2007-03-28
US7192741B2 (en) 2007-03-20
EP1829972B1 (en) 2010-05-12
PT1600510E (pt) 2007-06-25
EP1829971A3 (en) 2008-06-04
US20070031934A1 (en) 2007-02-08
EP1806407B1 (en) 2010-05-05
EP1829971A1 (en) 2007-09-05
ATE474053T1 (de) 2010-07-15
KR20090037485A (ko) 2009-04-15
DK1808488T3 (da) 2010-10-18
JP4500044B2 (ja) 2010-07-14
NO338477B1 (no) 2016-08-22
ES2285630T3 (es) 2007-11-16
DK1842919T3 (da) 2010-08-16
EP1842919B1 (en) 2010-05-05
DE60237048D1 (de) 2010-08-26
DE60215502T2 (de) 2007-08-30
ATE466941T1 (de) 2010-05-15
EP1404872B1 (en) 2006-10-18
KR100942117B1 (ko) 2010-02-12
ES2274045T3 (es) 2007-05-16
US20070031936A1 (en) 2007-02-08
JP2010131024A (ja) 2010-06-17
ATE467682T1 (de) 2010-05-15
JP2004533262A (ja) 2004-11-04
NZ530218A (en) 2005-09-30
EP1808488A3 (en) 2007-11-14
CA2450020C (en) 2013-08-13
EP1829972A2 (en) 2007-09-05
HK1068652A1 (en) 2005-04-29
KR100942116B1 (ko) 2010-02-12
US7662591B2 (en) 2010-02-16
DK1845162T3 (da) 2010-08-16
ATE466942T1 (de) 2010-05-15
DE60236334D1 (de) 2010-06-17
US7659094B2 (en) 2010-02-09
AU2011202193B2 (en) 2011-09-29
DE60236333D1 (de) 2010-06-17
BR0210771A (pt) 2004-07-13
MXPA03011801A (es) 2005-03-07
ES2344074T3 (es) 2010-08-17
DK1404872T3 (da) 2007-02-19
BRPI0210771B1 (pt) 2015-12-22
ZA200309599B (en) 2006-05-31
EP1845162B1 (en) 2010-05-05
EP1808488A2 (en) 2007-07-18
US20070128717A1 (en) 2007-06-07
US20030199468A1 (en) 2003-10-23
ES2344072T3 (es) 2010-08-17
IL193373A (en) 2010-12-30
NO20040011L (no) 2004-03-03
DK1806407T3 (da) 2010-08-16
EP1829972A3 (en) 2007-10-24
ATE466943T1 (de) 2010-05-15
US7749733B2 (en) 2010-07-06
CA2812799C (en) 2016-01-26
EP1808488B1 (en) 2010-07-14
IL159674A0 (en) 2004-06-20
CN1524128A (zh) 2004-08-25
EP1600510A3 (en) 2006-02-22
JP5014443B2 (ja) 2012-08-29
US7736870B2 (en) 2010-06-15
ES2348174T3 (es) 2010-11-30
EP1842919A1 (en) 2007-10-10
DE60219221T2 (de) 2008-01-03
EP1404872A2 (en) 2004-04-07
EP1600510A2 (en) 2005-11-30
KR20090037960A (ko) 2009-04-16
DE60236379D1 (de) 2010-06-24
US20070026499A1 (en) 2007-02-01
JP5014444B2 (ja) 2012-08-29
US7736868B2 (en) 2010-06-15
US20070026498A1 (en) 2007-02-01
AU2011202193A1 (en) 2011-06-02
WO2003004704A2 (en) 2003-01-16
ES2344073T3 (es) 2010-08-17
IL159674A (en) 2009-02-11
US7655441B2 (en) 2010-02-02
US20070031935A1 (en) 2007-02-08
ES2344071T3 (es) 2010-08-17
CA2450020A1 (en) 2003-01-16
ATE343004T1 (de) 2006-11-15
EP1845162A1 (en) 2007-10-17
EP1806407A3 (en) 2008-06-04
DE60215502D1 (de) 2006-11-30
ATE358183T1 (de) 2007-04-15
SG143066A1 (en) 2008-06-27
US7736869B2 (en) 2010-06-15
EP1829971B1 (en) 2010-05-05
JP2010131025A (ja) 2010-06-17
IL193374A (en) 2010-12-30
DK1600510T3 (da) 2007-06-25
ATE466944T1 (de) 2010-05-15
US7951586B2 (en) 2011-05-31
ES2344070T3 (es) 2010-08-17
DE60236331D1 (de) 2010-06-17
US20070031933A1 (en) 2007-02-08
CA2812799A1 (en) 2003-01-16
DK1829972T3 (da) 2010-09-13
DE60219221D1 (de) 2007-05-10
CN1266282C (zh) 2006-07-26
EP1806407A2 (en) 2007-07-11
DE60236332D1 (de) 2010-06-17
WO2003004704A3 (en) 2003-10-16
AU2007234619B2 (en) 2011-06-02
DK1829971T3 (da) 2010-08-16
BRPI0210771B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
CY1107678T1 (el) Dna αλληλουχιες που εχουν ενεργητικοτητα αντι-καταστολεα
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
CY1118901T1 (el) Anti-il-12 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
EA200501524A1 (ru) Антитела против амилоида, композиции, способы и применения
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1108211T1 (el) Προφυλακτικη και θεραπευτικη αγωγη των μολυσματικων, αυτοανοσων και αλλεργικων νοσων με ενωσεις βασης μονοσακχαριτη
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
DE60005953D1 (de) Stapelbare statische mischelemente
ATE484201T1 (de) Verwendung von beta-cryptoxanthin
EA200702532A1 (ru) Антитела против мср-1, композиции, способы и применения
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
CY1110418T1 (el) Αναστολη της αλληλεπιδρασης μεταξυ οξειδωμενων πρωτεϊνων και cd36 ή ο μηχανισμος δρασης τους
DE60133366D1 (de) Irak-4 zusammensetzungen und deren verwendungen
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
ATE374834T1 (de) Methoden zur identifizierung evolutionär signifikanter änderungen in polynukleotid- und polypeptidsequenzen in domestizierten pflanzen und tieren
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
CY1110755T1 (el) Αντι-διπλα αντισωματα ιντεγκρινης, συνθεσεις, μεθοδοι και χρησεις
CY1116561T1 (el) Αντισωματα anti-alpha2 ιντεγκρινης και oi χρησεις τους